GE Healthcare has signed an agreement to invest up to $50m in Israeli start-up Pulsenmore and enter the homecare segment facilitating precision health.
The equity investment is intended to expedite the international acceptance of the homecare ultrasound solutions from Pulsenmore.
It will also support receipt of US Food and Drug Administration (FDA) approval and commercial expansion.
Apart from the investment, GE will collaborate with Pulsenmore to supply its products in Europe and various other markets once the product becomes commercially available.
Furthermore, the companies will partner to develop ultrasound-based healthcare offerings intended for the growing homecare market.
With its new self-operated prenatal home ultrasound solution, Pulsenmore is ideally positioned for the telehealth market.
On connecting to a smartphone, the solution allows pregnant women to perform self-scanning for remote clinical analysis by their healthcare provider.
A handheld ultrasound device that can be attached to the user’s smartphone and a mobile app that aids the patient in consulting a clinician in offline/online mode are included in the product offering.
The offering also includes a web application for clinician-side interaction with the platform and a software API that facilitates merging the company’s online services with health records.
The Pulsenmore device offers regular fetal ultrasound scanning and consultation as an offline application-guided service or online clinician-guided telecommunication service.
Pulsenmore CEO and founder Dr Elazar Sonnenschein said: “With GE Healthcare’s market leadership position and reach, we are one step closer to achieving our vision of making home ultrasound universally accessible for remote and reliable care, ultimately improving maternal health across the globe.
“Through this exciting partnership, we will accelerate the empowerment of women to proactively manage their pregnancy, in collaboration with their health care providers, and will lead the next wave of ultrasound innovation that will benefit patients and providers alike.”
The company is developing various other applications and devices, including remote follicular monitoring for women who undergo in-vitro fertilisation and remote monitoring for end-stage renal disease and chronic heart failure.
Last December, GE Healthcare concluded the acquisition of surgical visualisation company BK Medical for $1.45bn in cash.